CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis. - Rampotas A; Wong ZC; Gannon I; Brierley CK; Shen Y; Benlabiod C; Chee A; Khan S; Hayder N; Cheung GW; Mitsikakou M; Murphy E; et al. (Science translational medicine, 2026)